APLS INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – APLS

NEW YORK, July 24, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) resulting from allegations that Apellis may have issued materially misleading business information to the investing public. SO WHAT: If […]

NEW YORK, July 24, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) resulting from allegations that Apellis may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Apellis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=17734 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On July 17, 2023, the American Society of Retina Specialists issued a press release highlighting concerns with Syfovre, Apellis Pharmaceuticals’ new eye-disease drug. The release indicated that physicians have reported cases of eye inflammation in patients treated with the drug, including six instances of occlusive retinal vasculitis, a potentially blinding type of inflammation that blocks blood flow through the vessels that feed the retina.

On this news, the price of Apellis’ stock fell by $32.04 per share, or 37.92%, to close at $52.46 on July 17, 2023.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8879496

Previous Article

Magnitude 6.0 earthquake strikes off East Nusa Tenggara, Indonesia

Next Article

EB5 Capital’s Riverfront at the Navy Yard (JF8) Project Receives First I-829 Approval

Related Posts

Texas Cardiac Arrhythmia Institute physician led international workshop on cardiac arrhythmias

AUSTIN, Texas, Oct. 26, 2022 /PRNewswire/ — The executive medical director of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center recently led Venice Arrhythmias 2022, a biennial international workshop on cardiac arrhythmias held in Venice, Italy from October 13 to October 15, 2022. As Venice Arrhythmias president, Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., organized the programming […]

‫شركة Erickson “إريكسون” بدأت بتقييم البدائل الاستراتيجية لتسريع النمو في مجال لعمليات الجوية وMRO

بورتلاند، أوريغون، 7 أغسطس/آب 2021 /PRNewswire/ – أعلنت شركة إريكسون أنها وكلّت بنك Houlihan Loke ” بهوليهان لوك” لاستكشاف البدائل الاستراتيجية لتسريع نمو الشركة والحفاظ على موقعها الريادي في الصناعة. وقد صرّح دوج كيتاني، الرئيس التنفيذي والمدير قائلاً: “نسعى للحصول على شريك استراتيجي يشاركنا رؤيتنا والتزامنا تجاه العملاء والموظفين ويمكنه إضافة قيمة استراتيجية وتشغيلية لصناعة الطيران […]

Sweegen’s Bestevia® Rebaudioside M Approved in Europe

Forging the future with better sugar reduction solutions for food and beverages in the region. Rancho Santa Margarita, Calif., July 15, 2021 (GLOBE NEWSWIRE) — Sweegen’s footprint in Europe became stronger after the European Union Commission published its approval of Sweegen’s non-GMO Signature Bestevia Rebaudioside M (Reb M) for use in food and beverages. The […]